Caroline Loew - Mar 1, 2024 Form 4 Insider Report for Mural Oncology plc (MURA)

Role
Chief Executive Officer, Director
Signature
/s/ Maiken Keson-Brookes, attorney-in-fact for Caroline Loew
Stock symbol
MURA
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
4
Date filed
3/4/2024, 05:25 PM
Previous filing
Dec 18, 2023
Next filing
Jul 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MURA Ordinary Shares Award $0 +48.5K +23.71% $0.00 253K Mar 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MURA Stock Option (right to buy) Award $0 +90K $0.00 90K Mar 1, 2024 Ordinary Shares 90K $5.39 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of ordinary shares issuable under 48,475 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share of the Issuer upon vesting. These RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2024, subject to the reporting person's continued service with the Issuer.
F2 This option was granted on March 1, 2024. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2025 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer.